Today: 19 May 2026
Browse Category

Pfizer News 4 November 2025 - 2 December 2025

PFE Stock Today (Nov. 25, 2025): Pfizer Rises on Metsera Obesity Deal, PADCEV Approval and Options Surge

PFE Stock Today (Nov. 25, 2025): Pfizer Rises on Metsera Obesity Deal, PADCEV Approval and Options Surge

Pfizer shares rose 1.7% to $25.65 by early afternoon Tuesday after the company completed a $10 billion acquisition of obesity-drug developer Metsera. The stock traded between $25.24 and $25.96, with a market cap near $143 billion. Pfizer also reported new FDA approval for PADCEV plus Keytruda in bladder cancer and continued strong options activity at the $25 strike.
25 November 2025
···
Pfizer Stock News Today (PFE): Texas ADHD Settlement, New Antibody Partnership and Obesity Push – November 19, 2025

Pfizer Stock News Today (PFE): Texas ADHD Settlement, New Antibody Partnership and Obesity Push – November 19, 2025

Pfizer and Tris Pharma agreed to pay $41.5 million to settle Texas claims over adulterated ADHD drug Quillivant XR. Pfizer also announced a research deal with Nona Biosciences for antibody discovery. At the Jefferies Healthcare Conference, management reaffirmed $7.7 billion in cost cuts and a push into obesity drugs. PFE traded near $25.37 early Wednesday, slightly down from the prior close.
19 November 2025
····
Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer Stock Today (Nov. 18, 2025): PFE steadies near $25 as Pfizer launches multi‑tranche bond sale to help fund Metsera deal

Pfizer launched a U.S. dollar bond sale aiming to raise at least $5 billion to help fund its recent Metsera acquisition, which closed Nov. 13 for up to $10 billion. The offering may include up to seven tranches, with early talks on a 40-year note at about 125 basis points over Treasuries. Pfizer shares traded near $25.11 as of 16:12 UTC, little changed on the day.
18 November 2025
·····
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) Stock Today, November 12, 2025: Shares Nudge Higher as Jefferies Webcast Set, Metsera Deal Stays in Focus

Pfizer shares rose 1.7% to $25.94 Wednesday afternoon, trading in a narrow range ahead of next week’s CFO webcast at the Jefferies London Healthcare Conference. Investors are watching for updates on Pfizer’s $10 billion Metsera obesity-drug deal, with a shareholder vote set for November 13. Pfizer recently raised its 2025 EPS outlook and declared a $0.43 Q4 dividend. Market sentiment improved after positive media commentary.
12 November 2025
···
Pfizer Stock Surges on Trump Deal & Obesity Drug Drama – Is a Comeback Coming?

Pfizer (PFE) Stock Today — Nov 7, 2025: Metsera Bidding War Intensifies, Dividend Record Date, and What’s Moving the Share Price

Pfizer shares fell 2.3% to $24.28 amid heavy trading as a Delaware judge allowed Metsera to exit its deal with Pfizer, intensifying the takeover battle with Novo Nordisk. Pfizer is reportedly considering a higher bid ahead of Metsera’s Nov. 13 shareholder vote. The company marked its dividend record date today for a $0.43 payout. Earlier this week, Pfizer raised its 2025 EPS guidance after beating Q3 estimates.
7 November 2025
····
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer Stock’s Wild November Ride: Earnings Beat, Obesity Drug Battle & Bold Forecasts

Pfizer shares traded near $24.60 on Nov. 4, 2025, down about 8–9% year-to-date and over 60% from their 2021 peak. Q3 adjusted earnings beat forecasts at $0.87 per share, but revenue missed slightly at $16.65 billion. Pfizer raised its full-year profit outlook and reaffirmed revenue guidance. The company is locked in a takeover battle with Novo Nordisk for obesity drug developer Metsera.
4 November 2025
·····
1 2

Stock Market Today

  • Equinix (EQIX) Upgraded to Zacks Rank #2 Buy on Rising Earnings Estimates
    May 19, 2026, 1:28 PM EDT. Equinix (EQIX), a data center operator, has been upgraded to Zacks Rank #2 (Buy) due to rising earnings estimates, a key driver for stock prices. This Zacks rating reflects an improved earnings outlook based on consensus EPS (earnings per share) estimates from sell-side analysts. Institutional investors use these earnings trends to assess stock fair value, influencing large share transactions and price movements. For the fiscal year ending December 2026, Equinix is forecast to earn $42.52 per share. The upgrade underscores growing investor confidence in Equinix's business prospects and indicates potential upward momentum for its stock.

Latest articles

Chewy Slides After Consumer Warning

Chewy Slides After Consumer Warning

19 May 2026
Chewy shares fell 7.8% to $19.95 in midday trading Tuesday after CEO Sumit Singh warned of increased consumer spending pressure at a JPMorgan conference. Trading volume topped 10.3 million shares. The drop outpaced declines in the S&P 500 and Nasdaq. Chewy reports fiscal first-quarter results before markets open June 10.
Kroger Shares Trade as Investors Watch Price Cuts

Kroger Shares Trade as Investors Watch Price Cuts

19 May 2026
Kroger shares rose 3.8% to $70.89 in midday trading Tuesday, outpacing gains in Walmart and Costco as Amazon fell. The move extends Monday’s rally, with investors reacting to new CEO Greg Foran’s focus on pricing and store execution. No new earnings were released. Volume reached about 3.54 million shares.
Hut 8 shares fall again as AI infrastructure push grows

Hut 8 shares fall again as AI infrastructure push grows

19 May 2026
Hut 8 shares dropped 5.5% to $90.88 in midday Nasdaq trading Tuesday after the company announced a $16 million investment in water infrastructure for its River Bend AI data center in Louisiana. The project, agreed with West Feliciana Parish, includes a new well and water main, with completion expected in late 2026. Bitcoin prices remained steady near $76,486.
Go toTop